ARS Pharmaceuticals, Inc. - Common Stock SPRY 深 滬
等待開盤 10-27 09:30:00 美东时间
9.11
-0.540
-5.60%
華盛通- 最 高9.7588
- 今 開9.67
- 成交量 192.39万股
- 最 低 9.08
- 昨 收 9.65
- 總市值 9.00亿
- 52周最高 18.90
- 市盈率 靜 116.65
- 換手率 0.00%
- 52周最低 9.08
- 委 比 56.78%
- 總股本 9882.63万
- 歷史最高 63.41
- 量 比 1.15
- 振 幅 7.03%
- 歷史最低 2.55
- 每 手 1
- 風險率 2.40%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Spyre Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $316.2 Million
Spyre Therapeutics, a clinical-stage biotech company focused on treating inflammatory bowel disease and other immune-mediated conditions, announce the closing of its underwritten public offering. The company sold 17,094,594 shares, including 2,229,729 additional shares due to underwriters' option exercise, at $18.50 per share, resulting in approximately $316.2 million in gross proceeds. Jefferies, TD Securities, Leerink Partners, and Stifel acted...
10-15 20:15
ARS Pharmaceuticals Receives Favorable Decision from European Patent Office on Patent Related to neffy® (epinephrine nasal spray)
ARS Pharmaceuticals announced that the European Patent Office upheld the validity of its nasal spray epinephrine formulation patent in over 30 European countries. Earlier, the U.S. Patent and Trademark Office also upheld a related U.S. patent for treating type-1 hypersensitivity reactions, including anaphylaxis. The company's patents, covering its product **neffy®**, provide protection until at least 2039. **neffy®** is a nasal spray used for eme...
10-08 12:00
Spyre Therapeutics Announces Grants of Inducement Awards
Spyre Therapeutics granted stock options to purchase 42,500 shares to three non-executive employees under its 2018 Equity Inducement Plan. The options, approved on October 1, 2025, have an exercise price of $16.46, vesting over 10 years with 1/4 of shares vesting after the first year and monthly vesting of 1/48 thereafter, contingent on continued employment. The company focuses on developing therapies for inflammatory bowel disease and other immu...
10-03 20:05
ARS Pharmaceuticals Secures $250 Million Credit Agreement
ARS Pharmaceuticals ( ($SPRY) ) has provided an announcement. On September 29, ...
09-30 04:51
ARS Pharma secures $250M loan to accelerate Neffy rollout
ARS Pharmaceuticals (NASDAQ:SPRY) announced a $250M senior secured term loan with affiliates of RA Capital and OMERS Life Sciences. An initial $100M draw will support the commercial expansion of neffy...
09-30 04:19
ARS Pharmaceuticals Secures Up to $250 Million Loan Facility with RA Capital Management and OMERS Life Sciences to Accelerate U.S. Commercialization of neffy®
ARS Pharmaceuticals has secured a $250 million senior secured term loan facility with RA Capital and OMERS Life Sciences, with an initial $100 million borrowed to accelerate the commercial growth of its needle-free epinephrine nasal spray, **neffy**. The funding will also support marketing and medical affairs initiatives to generate real-world evidence about **neffy**'s effectiveness. **neffy** is steadily expanding its prescriber base across all...
09-29 20:05
ARS Pharma Urges FDA To Delay Approval Of Aquestive's Allergic Reaction Treatment
ARS Pharmaceuticals petitioned the FDA to delay approval of Aquestive's epinephrine film, citing safety, dosing, and cardiovascular concerns.
09-24 00:01
Spyre Therapeutics Doses First Patient in Pioneering Phase 2 SKYWAY Basket Trial of SPY072, the First Anti-TL1A Antibody Studied in Rheumatic Diseases
Spyre Therapeutics has initiated a Phase 2 basket trial of SPY072, an investigational antibody targeting TL1A, for the treatment of rheumatoid arthritis (RA), psoriatic arthritis (PsA), and axial spondyloarthritis (axSpA). SPY072, designed for quarterly or twice-yearly subcutaneous dosing, aims to provide superior convenience and durability. The SKYWAY trial is expected to deliver proof-of-concept data for all three indications in 2026. SPY072's ...
09-15 12:00
Real-World Evidence Supports Clinical Effectiveness of neffy® (epinephrine nasal spray) in Patients Experiencing Anaphylaxis
ARS Pharmaceuticals Inc announced real-world evidence showing that nearly 90% of 545 patients with anaphylaxis symptoms during oral food challenge and allergen immunotherapy were successfully treated with a single dose of neffy (epinephrine nasal spray). This success rate is comparable to that of epinephrine injection, supporting neffy's clinical effectiveness as a needle-free alternative. The findings, accepted for publication in the Annals of A...
09-08 12:00
Catalyst Watch: Apple event, Oracle earnings, and Klarna leads an IPO blitz
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Read more about the events that may impact stock prices next week. Sunday - September...
09-06 03:00
